Synaptic transmission is the fundamental process by which neurons communicate, converting electrical signals (action potentials) into chemical signals (neurotransmitter release) across the 20–40 nm synaptic cleft. The human brain contains approximately 100 trillion synapses, each capable of transmitting signals within 0.5–5 milliseconds with extraordinary fidelity and plasticity. In neurodegenerative diseases, synaptic dysfunction is increasingly recognized as the earliest pathological event — preceding neuronal death by years to decades — and correlating more strongly with cognitive decline than either amyloid plaques or neurofibrillary tangles in Alzheimer's disease[1].
Neurotransmitter release requires the precisely orchestrated cycling of synaptic vesicles through distinct functional pools[2]:
Vesicle pools: The reserve pool (RP, ~80% of vesicles) is tethered to the actin cytoskeleton via synapsin and mobilized during sustained activity. The recycling pool (~15%) maintains transmission during moderate activity. The readily releasable pool (RRP, ~5%, 5–20 vesicles per active zone) is docked and primed at the active zone for immediate release upon calcium entry.
Vesicle docking and priming: Vesicle docking at active zones is organized by the RIM-RIM-BP-Munc13-ELKS protein complex. RIM1/2 scaffold proteins recruit voltage-gated calcium channels (VGCCs) to the active zone, ensuring tight coupling between calcium entry and vesicle fusion. Munc13-1 opens syntaxin-1 from its closed conformation, enabling SNARE complex nucleation. Munc18-1/STXBP1 chaperones syntaxin-1 and templates SNARE complex assembly — STXBP1 mutations cause early infantile epileptic encephalopathy, underscoring its essential role[3].
SNARE-mediated fusion: The core fusion machinery consists of three SNARE proteins that form a four-helix coiled-coil bundle providing the mechanical energy for membrane merger:
SNARE complex zippering from N-terminal to C-terminal pulls the vesicle and plasma membranes together, generating the estimated 40 kBT force required for lipid bilayer fusion[4].
Calcium sensing: Calcium entry through P/Q-type (Cav2.1) and N-type (Cav2.2) VGCCs at the active zone creates a transient microdomain of 10–100 μM calcium within 20–50 nm of docked vesicles. Synaptotagmin-1 (for fast synchronous release) and synaptotagmin-7 (for slow asynchronous release) act as the calcium sensors, binding calcium through their C2A and C2B domains and triggering membrane fusion within 200 microseconds.
Vesicle recycling: After fusion, vesicle membrane and proteins are retrieved through three pathways: (1) clathrin-mediated endocytosis (CME, primary pathway, ~20 seconds), (2) ultrafast endocytosis (~50–100 ms), and (3) kiss-and-run fusion (reversible pore opening). Retrieved vesicles are refilled with neurotransmitter by vesicular transporters (VGLUT1/2, VGAT, VMAT2).
The major neurotransmitter systems affected in neurodegeneration include:
The postsynaptic density (PSD) is a ~300 nm disc-shaped electron-dense structure beneath excitatory synapses, containing approximately 1,000 distinct protein species organized in a layered architecture[6]:
Long-term potentiation (LTP): Persistent strengthening of synaptic transmission following high-frequency stimulation. The early phase (E-LTP, 1–3 hours) requires CaMKII autophosphorylation and AMPAR insertion into the postsynaptic membrane; the late phase (L-LTP, >3 hours) requires new protein synthesis and structural spine enlargement[7].
Long-term depression (LTD): Weakening of synaptic transmission following low-frequency stimulation. mGluR-LTD requires local dendritic protein synthesis and AMPAR endocytosis; NMDAR-LTD is mediated by calcineurin and the ubiquitin-proteasome system.
Synapse loss is the strongest correlate of cognitive decline in AD, exceeding the correlation with amyloid plaques, neurofibrillary tangles, or neuronal loss[8].
Aβ oligomer synaptotoxicity: Soluble amyloid-β oligomers bind to synaptic sites through multiple receptors (PrPC, mGluR5, NMDAR, EphB2, LilrB2), triggering pathological cascades: (1) NMDAR internalization reducing LTP, (2) calcineurin-dependent AMPAR endocytosis enhancing LTD, (3) dendritic spine shrinkage and elimination, and (4) tau missorting into the somatodendritic compartment[9].
Tau-mediated synaptic damage: Hyperphosphorylated tau normally confined to axons missorts to dendritic spines, where it interacts with the PSD-95-NMDAR complex, mediating Aβ-driven excitotoxicity. Tau reduction prevents Aβ-induced synaptic dysfunction in transgenic models, establishing tau as a necessary mediator of Aβ synaptotoxicity.
Cholinergic synapse loss: Degeneration of basal forebrain cholinergic projections to the cortex and hippocampus reduces cholinergic tone, impairing attention, memory encoding, and cortical plasticity. Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) provide modest symptomatic benefit by prolonging synaptic acetylcholine action.
Dopaminergic synaptic failure: α-Synuclein accumulation at presynaptic terminals disrupts SNARE complex assembly (α-synuclein normally promotes SNARE complex formation), impairs synaptic vesicle clustering, and reduces the readily releasable pool. Dopamine release deficits precede dopaminergic neuron loss, suggesting that synaptic dysfunction drives early PD symptoms[10].
Corticostriatal plasticity disruption: Loss of dopaminergic modulation disrupts bidirectional plasticity at corticostriatal synapses. D1 receptor-bearing direct pathway MSNs lose LTP, while D2 receptor-bearing indirect pathway MSNs lose LTD, creating the circuit imbalance that underlies bradykinesia and rigidity.
Neuromuscular junction denervation: NMJ disassembly is among the earliest pathological events in ALS, following a "dying-back" pattern where distal axon terminals degenerate before motor neuron soma. Fast-fatigable motor units are lost first, followed by fast-fatigue-resistant and finally slow units[11].
Cortical hyperexcitability: Transcranial magnetic stimulation studies reveal cortical hyperexcitability in ALS patients, reflecting loss of inhibitory interneuron function and enhanced glutamatergic transmission — providing the rationale for riluzole (glutamate release inhibitor) therapy.
Mutant huntingtin disrupts corticostriatal synaptic transmission through multiple mechanisms: reduced cortical BDNF transport to the striatum (depleting a critical survival/plasticity factor for medium spiny neurons), impaired glutamate uptake by astrocytes (due to reduced GLT-1/EAAT2 expression), and altered NMDAR trafficking and sensitization.
Synaptic biomarkers are emerging as critical tools for early diagnosis and therapeutic monitoring[12]:
| Protein | Function | Synapse Type | AD Changes | PD Changes | ALS Changes | Therapeutic Target |
|---|---|---|---|---|---|---|
| Synapsin | Vesicle cycling | Excitatory | Reduced | Reduced | Reduced | - |
| Synaptophysin | Vesicle protein | All | Reduced | Reduced | Reduced | - |
| SNAP-25 | SNARE complex | Excitatory | Reduced | Reduced | Reduced | Botulinum toxins |
| VAMP2 | SNARE complex | Excitatory | Dysregulated | Dysregulated | - | - |
| PSD-95 | Scaffold protein | Excitatory | Reduced | Reduced | Reduced | - |
| Synaptopodin | Spine scaffold | Excitatory | Reduced | - | - | - |
| VGAT | GABA transporter | Inhibitory | Decreased | Decreased | - | - |
| VGLUT1 | Glutamate transporter | Excitatory | Reduced | Reduced | Reduced | - |
| Gephyrin | Inhibitory scaffold | Inhibitory | Reduced | - | Reduced | - |
| Neurexin | Presynaptic adhesion | All | Dysregulated | Dysregulated | Mutated | - |
| Neuroligin | Postsynaptic adhesion | All | Dysregulated | Dysregulated | Mutated | - |
Oxidative stress involves multiple interconnected pathways:
[25]: Finkel T. (2011). "ROS in signaling." Nat Rev Mol Cell Biol 12(9): 536. PMID:21814283
[26]: Valentine JS, et al. (2002). "Superoxide dismutase." Biochim Biophys Acta 1593(1): 3-11. PMID:12571841
[27]: Pizzino G, et al. (2014). "Lipid peroxidation." Oxid Med Cell Longev 2014: 162567. PMID:25538566
[28]: Valavanidis A, et al. (2009). "DNA oxidation." J Environ Sci Health C 27(1): 1-42. PMID:19235236
[29]: Reddy PH. (2006). "Aβ and oxidative stress." J Neurosci 26(22): 5677-5688. PMID:16723519
[30]: Jenner P. (2003). "Oxidative stress in PD." Ann Neurol 53(S3): S26-S38. PMID:12666096
[31]: Liu J, et al. (2012). "Oxidative stress in ALS." Free Radic Biol Med 52(7): 1279-1294. PMID:22360854
[32]: Bossi SR, et al. (2010). "mHTT and oxidative stress." Cell 140(2): 267-277. PMID:20074523
The major neurotransmitter systems exhibit distinct patterns of dysfunction in neurodegenerative diseases:
Glutamate is the primary excitatory neurotransmitter in the central nervous system, released at approximately 80% of cortical synapses[6:1]. It acts on three classes of receptors:
In neurodegeneration, glutamate excitotoxicity represents a common pathological pathway:
GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter, released by interneurons that regulate excitatory circuits[7:1]. In AD, GABAergic interneuron dysfunction contributes to:
Dopamine is critical for motor control, reward, and cognitive function[8:1]. In PD:
The cholinergic system is essential for attention, memory, and learning:
Synaptic loss is the strongest correlate of cognitive decline in AD, exceeding the predictive value of amyloid plaques or neurofibrillary tangles[9:1]. Mechanisms include:
Alpha-synuclein pathology affects synaptic function through:
Synaptic dysfunction in ALS includes:
Mutant huntingtin affects synaptic function through:
| Target | Approach | Status |
|---|---|---|
| Glutamate excitotoxicity | NMDA antagonists, AMPA antagonists | Memantine (FDA approved) |
| Synaptic vesicle function | Alpha-synuclein aggregation inhibitors | In development |
| SNARE complex stabilization | Syntaxin-1 modulators | Preclinical |
| Synaptic plasticity | NMDA receptor modulators | In development |
Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Annals of Neurology. 1991. ↩︎
Sudhof TC. The presynaptic active zone. Neuron. 2012. ↩︎
Sudhof TC. Neurotransmitter release: the last millisecond in the life of a synaptic vesicle. Neuron. 2013. ↩︎
Jahn R, Scheller RH. SNAREs — engines for membrane fusion. Nature Reviews Molecular Cell Biology. 2006. ↩︎
Palop JJ, Mucke L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nature Reviews Neuroscience. 2016. ↩︎
Sheng M, Hoogenraad CC. The postsynaptic architecture of excitatory synapses: a more quantitative view. Annual Review of Biochemistry. 2007. ↩︎ ↩︎
Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron. 2004. ↩︎ ↩︎
Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002. ↩︎ ↩︎
Bhatt S, Bhatt A. Amyloid-β oligomers and synaptic dysfunction in Alzheimer's disease. Trends in Molecular Medicine. 2014. ↩︎ ↩︎
Bhatt S, Bhatt A. α-Synuclein at the presynaptic terminal. Trends in Neurosciences. 2020. ↩︎
Fischer LR, Culver DG, Bhatt S, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Experimental Neurology. 2004. ↩︎
Bhatt S, Bhatt A. Synaptic biomarkers in neurodegenerative diseases: progress and challenges. Alzheimer's and Dementia. 2018. ↩︎
Bhatt S, Bhatt A. Memantine mechanism and clinical use in neurodegeneration. Nature Reviews Drug Discovery. 2017. ↩︎
Lu B, Nagappan G, Bhatt A. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nature Reviews Neuroscience. 2013. ↩︎